Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 24 May 2024 18:22:55 +0200Thu, 18 Apr 2024 14:57:00 +0200Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/alymsysHuman medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/alymsysThu, 18 Apr 2024 14:57:00 +0200Human medicineAlymsys : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5286-en_1.pdfAlymsys : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5286-en_1.pdfThu, 18 Apr 2024 13:06:00 +0200Human medicine